Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis

Abstract Introduction This study aims to evaluate the clinical efficacy and safety profiles of various cyclin-dependent kinase 4/6 inhibitors(CDK4/6i) when administered alongside endocrine therapy (ET) in individuals diagnosed with advanced or metastatic breast cancer characterized by hormone recept...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Yuan Liu, Tongtong Ren, Xu Chen, Qinglan He, Xinchun Wang, Lisha Tang
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMC 2025-10-01
Seri Bilgileri:	BMC Cancer
Konular:	CDK4/6 inhibitor Endocrine therapy Metastatic breast cancer Efficacy Safety
Online Erişim:	https://doi.org/10.1186/s12885-025-14841-2
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!